| Literature DB >> 32566630 |
Álvaro Romo-Ibáñez1, Elisabeth Calatrava-Hernández2, Blanca Gutiérrez-Soto3, Mercedes Pérez-Ruiz2, José María Navarro-Marí2, José Gutiérrez-Fernández1,2.
Abstract
BACKGROUND: Antibiotic resistance is a serious public health challenge exacerbated by the widespread use of β-lactam and glycopeptide antibiotics. The identification of resistances is crucial, and CHROMID ESBL medium has been developed to detect enterobacteria with extended-spectrum β-lactamases (ESBL). The objective of this study was to evaluate the potential of this medium to detect other types of resistant bacteria.Entities:
Keywords: CHROMID ESBL medium; Multiresistant bacteria; chromogenic media
Year: 2020 PMID: 32566630 PMCID: PMC7290529 DOI: 10.21037/atm.2020.02.158
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Coloring of the different species studied on the CHROMID ESBL plate. (A) K. pneumoniae; (B) K. oxytoca; (C) P. mirabilis; (D) Citrobacter spp.; (E) E. coli; (F,G) P. aeruginosa; (H) S. maltophilia; (I,J) E. cloacae; (K) A. baumannii; (L) vancoR E. faecium.
Number of isolates grown on CHROMID ESBL medium, percentage by microorganism, and mean percentage by type of resistance
| Resistance mechanisms | Microorganisms | No. isolates | Positive growth (%) | Mean % growth |
|---|---|---|---|---|
| ESBL |
| 43 | 43 (100.0) | 100.0 |
|
| 2 | 2 (100.0) | ||
|
| 38 | 38 (100.0) | ||
| Carbapenemases | 94.7 | |||
| KPC |
| 8 | 8 (100.0) | 100.0 |
| IMPase |
| 16 | 15 (93.8) | 94.1 |
|
| 1 | 1 (100.0) | ||
| VIM |
| 4 | 4 (100.0) | 91.7 |
|
| 3 | 2 (66.7) | ||
|
| 3 | 3 (100.0) | ||
|
| 1 | 1 (100.0) | ||
|
| 1 | 1 (100.0) | ||
| OXA |
| 15 | 15 (100.0) | 95.0 |
|
| 4 | 4 (100.0) | ||
|
| 1 | 0 (0) | ||
| AmpC |
| 2 | 1 (50.0) | 80.0 |
|
| 1 | 1 (100.0) | ||
|
| 7 | 4 (57.1) | ||
|
| 16 | 16 (100.0) | ||
|
| 2 | 2 (100.0) | ||
|
| 2 | 1 (50.0) | ||
|
| 2 | 2 (100.0) | ||
|
| 1 | 1 (100.0) | ||
|
| 1 | 0 (0) | ||
|
| 1 | 0 (0) | ||
| Other mechanisms |
| 3 | 3 (100.0) | 100.0 |
ESBL, extended-spectrum β-lactamases; KPC, Klebsiella pneumoniae carbapenemases; IMPase, carbapenemases type IMP; VIM, Verona integron-encoded metallo-beta-lactamase; OXA, oxacillinases.
Number of isolates showing halos ≥1.5 cm (susceptibility, S) or not (resistance, R) around cefoxitin (FOX), cefepime (FEP), and imipenem (IMP) disks according to the type of resistance
| Mechanisms | Microorganisms | IMP/FEP/FOX | Total | |||||
|---|---|---|---|---|---|---|---|---|
| S/S/S | S/R/S | R/R/R | S/S/R | R/S/R | S/R/R | |||
| Other mechanisms |
| – | – | – | – | 3 | – | 3 |
| AmpC |
| 1 | – | – | – | – | – | 1 |
|
| 2 | – | – | – | – | – | 2 | |
|
| – | – | 1 | – | – | – | 1 | |
|
| – | – | – | 2 | – | – | 2 | |
|
| 2 | 1 | – | 12 | – | 1 | 16 | |
|
| 4 | – | – | – | – | – | 4 | |
|
| 1 | – | – | – | – | – | 1 | |
|
| 1 | – | – | – | – | – | 1 | |
| CBP | ||||||||
| OXA |
| – | – | – | – | – | – | 4 |
|
| – | – | 1 | 14 | – | – | 15 | |
| VIM |
| 1 | – | – | – | – | – | 1 |
|
| – | – | 1 | – | – | – | 1 | |
|
| 2 | – | – | 1 | – | – | 3 | |
|
| – | – | – | 2 | – | – | 2 | |
|
| 1 | – | – | 3 | – | – | 4 | |
| IMPase |
| – | – | – | 1 | – | – | 1 |
|
| – | – | 5 | – | 10 | – | 15 | |
| KPC |
| 4 | – | 3 | 1 | – | – | 8 |
| ESBL |
| 2 | – | – | – | – | – | 2 |
|
| 38 | – | – | – | – | – | 38 | |
|
| 36 | 7 | – | – | – | – | 43 | |
CBP, carbapenemases; ESBL, extended spectrum β-lactamases; KPC, Klebsiella pneumoniae carbapenemases; IMPase, carbapenemases type IMP; VIM, Verona integron-encoded metallo-beta-lactamase; OXA, oxacillinases.
Number of positive episodes of each bacterium by type of sample
| Microorganisms | Positive samples (%) | ||||
|---|---|---|---|---|---|
| Total | Rectal swabs | Pharyngeal swabs | Other | Isolate description | |
|
| 55 | 45 (81.8) | 6 (10.9) | 4 (7.3) | 6 OXA-23 |
| VancoR enterococci | 20 | 20 (100.0) | 0 (0) | 0 (0) | 15 |
| ESBL | 5 | 5 (100.0) | 0 (0) | 0 (0) | – |
| ESBL | 68 | 63 (92.6) | 3 (4.4) | 2 (2.9) | – |
|
| 23 | 21 (91.3) | 1 (4.3) | 1 (4.3) | 22 IMPase; 1 VIM |
|
| 2 | 2 (100.0) | 0 (0) | 0 (0) | 2 VIM |
| MetiR | 48 | 12 (25.0) | 36 (75.0) | 0 (0) | – |
|
| 23 | 12 (52.2) | 11 (47.8) | 0 (0) | – |
|
| 1 | 0 (0) | 1 (100.0) | 0 (0) | – |
|
| 1 | 0 (0) | 1 (100.0) | 0 (0) | – |
OXA, oxacillinases; VancoR, vancomycin-resistant; ESBL, extended-spectrum β-lactamases; IMPase, carbapenemases type IMP; VIM, Verona integron-encoded metallo-beta-lactamase; MetiR, methicillin-resistant.
Comparison of episodes in which both types of sample were available
| Rectal swabs | Pharyngeal swabs | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MetiR |
| ESBL |
| VancoR Enterococci |
| ||||||||||||
| Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | ||||||
| Yes | 0 | 0 | 5 | 1 | 5 | 3 | 6 | 3 | 0 | 1 | 0 | 5 | |||||
| No | 2 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |||||
MetiR, methicillin-resistant; ESBL, extended-spectrum β-lactamases; VancoR, vancomycin-resistant.